WARRINGTON, Pa., May 9, 2012 /PRNewswire/ -- Discovery Laboratories, Inc.

® (lucinactant) and U.S. marketing clearance for the initial AFECTAIR® device, the Company is implementing its plans to build U.S. commercial and medical affairs capabilities, and to advance its SURFAXIN LS(TM) and AEROSURF®

WARRINGTON, Pa., May 1, 2012 /PRNewswire/ -- Discovery Laboratories, Inc.

® (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. SURFAXIN is the first synthetic, peptide-containing surfactant approved for use in neonatal medicine. In February 2012, the initial AFECTAIR®

Equity Research for the following companies: Exxon Mobil (NYSE:XOM), American Eagle (NYSE:AEO), Discovery Laboratories (NASDAQ:DSCO), NVR (NYSE:NVR), Chesapeake Energy (NYSE:CHK), and Microsoft (NASDAQ:MSFT).